Investor Highlights


  • Investor Presentation - view here
  • Quarterly Shareholder Update - view here
  • Investment Summary - view here

Aptar Pharma Pays Pharmaxis US $5m to Acquire Orbital Technology

  • Drug delivery leader Aptar Pharma exercises option for a worldwide license to the “Orbital” technology for $US2.5m and a subsequent option for an outright purchase of the technology for a further US$2.5 million.
  • Aptar Pharma’s decision supported by the potential for safe and convenient administration of high dose treatments to the lungs
  • Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler
Read full media release - pdf

Pharmaxis Strengthens Clinical Development Oncology Capability with The Appointment of Dr Jana Baskar as Chief Medical Officer

Pharmaxis Limited (ASX:PSX), a clinical stage drug development company developing novel therapies to treat inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Jana Baskar to the role of Chief Medical Officer.

Dr Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies.

“We are delighted to welcome Dr Baskar to Pharmaxis, where his deep experience leading clinical programs will be an asset to the continued advancement of our pipeline,” commented Gary Phillips, Chief Executive Officer of Pharmaxis. “Dr Baskar brings significant oversight, clinical development and strategic expertise, having previously guided numerous programs through all phases of development. His extensive background and experience will be particularly valuable as the Company progresses its lead asset, PXS-5505, towards clinical proof of concept in myelofibrosis and other oncology indications.”

Read full media release - pdf

MST Access: Clinical trials on track; news flow ahead

Chris Kallos of MST Access discusses Pharmaxis clinical trial program with CEO Gary Phillips.

Watch the interview here.

MST Financial (“MST”) materials, or any portion thereof, may not be reproduced, sold or redistributed without the prior and written consent of MST. MST Access reports, updates, video interviews and other materials produced by MST Access have generally been engaged and paid by the subject company for ongoing research coverage. Please refer to full disclosures and disclaimers in the company-specific reports. 

Pharmaxis Launches New International Clinical Trial Sites in Phase 2 Bone Marrow Cancer Trial

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has initiated the first of 5 new trial sites in Taiwan as it progresses the phase 2 clinical trial of its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis. These latest centres join 11 active sites across Australia and South Korea with a further 4 centres in the US expected to come on stream in coming months.  

Pharmaxis CEO Gary Phillips said, “This planned initiation of new trial sites in Taiwan will bring the total number of active sites to 16.  The study is making pleasing progress as it builds to a recruitment target of 24 patients. This latest expansion of sites is part of a focused effort by the company to bring patients into the trial and deliver results by the year end.”  

Mr Phillips added, “We know from the earlier dose escalation study that PXS-5505 will fully block the LOX enzymes that play a fundamental part in the bone marrow fibrosis that characterises myelofibrosis, giving hope that the drug can modify the course of the disease.  The good tolerability profile, which is a key differentiator from current standard of care, was first demonstrated in healthy volunteers and then backed up by myelofibrosis patients on 1 month of therapy in the dose escalation study.  I am pleased to report that we now have experience with patients who have had 3 or more months of therapy on PXS-5505 and that the good tolerability profile is being maintained.”

Read full media release - pdf

First Patients Dosed in Trial of Pharmaxis Scar Reduction Drug

  • Collaboration with research team led by Professor Fiona Wood AM doses first patients in trial of 50 patients with established scars
  • 3-month placebo-controlled study to report safety and tolerability endpoints as well as measures of scar structure and appearance in 2H 2022
  • PXS-6302 is a first in class topical inhibitor of the lysyl oxidase enzymes that are involved in formation and maintenance of scars; a potential breakthrough treatment for patients with problematic scars in a market estimated at US$3.5 billion per year
Read full media release - pdf